Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Image

GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows

Article Created on 17 Feb 2026 by GSK News Feed

Reduction observed in RSV-related hospitalisations in adults aged ≥60 years

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement